Literature DB >> 17953713

Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines.

Yu Nakamura1, Daisuke Matsubara, Akiteru Goto, Satoshi Ota, Oguni Sachiko, Shumpei Ishikawa, Hiroyuki Aburatani, Keiji Miyazawa, Masashi Fukayama, Toshiro Niki.   

Abstract

In this study we explored the mechanisms of constitutive activation of c-Met in lung adenocarcinoma cell lines. First, we examined levels of c-Met and phospho-c-Met (Y1234/Y1235) in a panel of lung adenocarcinoma cell lines by Western blot analysis. c-Met expression was found in 12 of 14 cell lines and an overall correlation between the expressions of c-Met and phospho-c-Met was noted. c-Met was constitutively activated particularly at high levels in five cell lines (PC3, LC-2/ad, L27, H1648, and H2009). c-Met amplification was identified in L27 and H1648 by single nucleotide polymorphism array analysis, but no mutations were identified in the Sema domain or in any part of the cytoplasmic domain of c-Met. Experiments with neutralizing anti-hepatocyte growth factor (HGF) antibody, scatter assay using Madin-Darby canine kidney cells, and Western blotting on conditioned media of the cell lines revealed that the constitutive phosphorylation of c-Met was largely ligand-independent. The inhibition of cell-matrix adhesion induced the dephosphorylation of c-Met in the five cell lines tested. This was accompanied by downregulation of c-Met in three of the five cell lines. In contrast, the inhibition of cell-cell adhesion by neutralizing E-cadherin antibody had a minimal effect on the expression and phosphorylation of c-Met. These results reveal three features of the constitutive activation of c-Met in our panel of lung adenocarcinoma cell lines: (i) it correlates with c-Met overexpression, either with or without gene amplification; (ii) it is largely ligand-independent; and (iii) it depends on cell-matrix adhesion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17953713     DOI: 10.1111/j.1349-7006.2007.00640.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  19 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 2.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

3.  Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Authors:  Daniel V T Catenacci; Les Henderson; Shu-Yuan Xiao; Premal Patel; Robert L Yauch; Priti Hegde; Jiping Zha; Ajay Pandita; Amy Peterson; Ravi Salgia
Journal:  Cancer Discov       Date:  2011-12       Impact factor: 39.397

4.  Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.

Authors:  V W Y Lui; E Y L Wong; K Ho; P K S Ng; C P Y Lau; S K W Tsui; C-M Tsang; S-W Tsao; S H Cheng; M H L Ng; Y K Ng; E K Y Lam; B Hong; K W Lo; T S K Mok; A T C Chan; G B Mills
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

5.  Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

Authors:  Elisa Vigna; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Cristina Basilico; Fiorella Petronzelli; Paolo M Comoglio
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

6.  Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Authors:  Daisuke Matsubara; Shumpei Ishikawa; Oguni Sachiko; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

7.  HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.

Authors:  Mukaddes Gumustekin; Aydanur Kargi; Gulay Bulut; Aysim Gozukizil; Cagnur Ulukus; Ilhan Oztop; Nese Atabey
Journal:  Pathol Oncol Res       Date:  2011-07-21       Impact factor: 3.201

8.  NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.

Authors:  Takeshi Kubota; Hiroaki Taiyoh; Atsushi Matsumura; Yasutoshi Murayama; Daisuke Ichikawa; Kazuma Okamoto; Hitoshi Fujiwara; Hisashi Ikoma; Masayoshi Nakanishi; Shojiro Kikuchi; Chouhei Sakakura; Toshiya Ochiai; Yukihito Kokuba; Hiroki Taniguchi; Teruhisa Sonoyama; Kunio Matsumoto; Toshikazu Nakamura; Eigo Otsuji
Journal:  Clin Exp Metastasis       Date:  2009-02-21       Impact factor: 5.150

9.  Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling.

Authors:  Kazuya Machida; Steven Eschrich; Jiannong Li; Yun Bai; John Koomen; Bruce J Mayer; Eric B Haura
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

10.  Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Authors:  Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.